SCHEMBL21688022

SCHEMBL21688022

N#Cc1ccc2c(c1)c1ccccc1n2-c1cc(-c2cccc([Si](c3ccccc3)(c3ccccc3)c3ccccc3)c2)ccc1C#N

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 2/20 0.34
ALDH1A3 P47895 1/20 0.33
ADORA2A P29274 1/20 0.32
ALDH1A1 P00352 5/20 0.32
LMNA P02545 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MAPK1 P28482 2/20 0.32
HPGD P15428 1/20 0.32
RORC P51449 3/20 0.32
HIF1A Q16665 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
MEN1 O00255 2/20 0.31
CYP1A2 P05177 2/20 0.31
CYP3A4 P08684 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21688010 0.97 ALDH1A3 (0.35) ALDH1A3ADORA2AALDH1A1LMNASMN1; SMN2
SCHEMBL21687900 0.94 PTGER4 (0.35) PTGER4ALDH1A1LMNASMN1; SMN2MAPK1
SCHEMBL21687895 0.93 PTGER4 (0.34) PTGER4ALDH1A3ADORA2AALDH1A1LMNA
SCHEMBL21687976 0.92 ALDH1A1 (0.36) ALDH1A1LMNASMN1; SMN2MAPK1HPGD
SCHEMBL21687522 0.92 PTGER4 (0.33) PTGER4ALDH1A3RORC
SCHEMBL21687714 0.90 ALDH1A3 (0.35) PTGER4ALDH1A3ADORA2AALDH1A1LMNA
SCHEMBL21687712 0.90 CYP11B1 (0.34) ALDH1A3ALDH1A1LMNASMN1; SMN2MAPK1
SCHEMBL21687746 0.90 PTGER4 (0.33) PTGER4RORCCYP11B1CYP11B2
SCHEMBL21687685 0.89 PTGER4 (0.34) PTGER4ALDH1A1LMNASMN1; SMN2MAPK1
SCHEMBL21688254 0.88 MEN1 (0.32) PTGER4ADORA2AALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11201300-B2 Condensed cyclic compound and organic light-emitting device including condensed cyclic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2021-12-14 US disclosed
US-20200044168-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200044168-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND CRY1, CCNL2, CCNE2 PTGER4 553/4885ALDH1A3 1446/4885ADORA2A 4717/4885
US-11201300-B2 Condensed cyclic compound and organic light-emitting device including condensed cyclic compound CRY1, CCNL2, CCNE2 PTGER4 553/4885ALDH1A3 1446/4885ADORA2A 4717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.